Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Cash & Current Investments (2016 - 2025)

Historic Cash & Current Investments for Gyre Therapeutics (GYRE) over the last 17 years, with Q3 2025 value amounting to $60.0 million.

  • Gyre Therapeutics' Cash & Current Investments rose 13899.15% to $60.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $60.0 million, marking a year-over-year increase of 13899.15%. This contributed to the annual value of $26.7 million for FY2024, which is 2028.11% down from last year.
  • Latest data reveals that Gyre Therapeutics reported Cash & Current Investments of $60.0 million as of Q3 2025, which was up 13899.15% from $54.4 million recorded in Q2 2025.
  • Gyre Therapeutics' Cash & Current Investments' 5-year high stood at $131.0 million during Q1 2021, with a 5-year trough of $6.9 million in Q3 2023.
  • Moreover, its 5-year median value for Cash & Current Investments was $33.5 million (2023), whereas its average is $43.8 million.
  • As far as peak fluctuations go, Gyre Therapeutics' Cash & Current Investments tumbled by 8470.95% in 2023, and later skyrocketed by 26456.76% in 2024.
  • Quarter analysis of 5 years shows Gyre Therapeutics' Cash & Current Investments stood at $49.4 million in 2021, then crashed by 48.99% to $25.2 million in 2022, then soared by 33.1% to $33.5 million in 2023, then fell by 20.28% to $26.7 million in 2024, then soared by 124.79% to $60.0 million in 2025.
  • Its Cash & Current Investments was $60.0 million in Q3 2025, compared to $54.4 million in Q2 2025 and $29.9 million in Q1 2025.